Beneficial effect of low dose G-CSF and cyclosporin-A in a case of chronic neutropenia.

1. Nano R, Invernizzi R, Rezzani R, Gerzeli G. Qualitative and quantitative study of dihydrofolate reductase in myelodysplastic syndromes. Acta Haematol 1988; 79: 198-201. 2. Nano R, Gerzeli G, Invernizzi R, Supino R. A qualitative and quantitative cytochemical assay of dihydrofolate reductase in erythroid cells. Acta Histochem 1989; 85:51-8. 3. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodyspplastic syndromes. Blood 1997; 89:2079-88. 4. Le Beau MM, Espinosa R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 1993; 90:5484-8. 5. Anagnou NP, Antonarakis SE, O’Brien SJ, Modi WS, Nienhuis AW. Chromosomal localization and racial distribution of the polymorphic human dihydrofolate reductase pseudogene (DHFRP1). Am J Hum Genet 1988; 42:345-52. 6. Maurer BJ, Barker PE, Masters JN, Ruddle FH, Attardi G. Human dihydrofolate reductase gene is located in chromosome 5 and is unlinked to the related pseudogenes. Proc Natl Acad Sci USA 1984; 81:1484-8. 7. Gerzeli G, De Piceis P. A critical examination of some histochemical methods for demonstrating tetrahydrofolate dehydrogenase. Histochem J 1972; 4:79-85. 8. Van den Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 1997; 94:1-7.